RA Capital Management L.P. Purchases Shares of 9,853,302 Artiva Biotherapeutics, Inc. (NASDAQ:ARTV)

RA Capital Management L.P. purchased a new position in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Free Report) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 9,853,302 shares of the company's stock, valued at approximately $152,234,000. Artiva Biotherapeutics makes up approximately 1.8% of RA Capital Management L.P.'s investment portfolio, making the stock its 17th biggest holding. RA Capital Management L.P. owned about 40.57% of Artiva Biotherapeutics as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. BNP Paribas Financial Markets purchased a new stake in shares of Artiva Biotherapeutics in the third quarter worth about $42,000. MetLife Investment Management LLC bought a new position in shares of Artiva Biotherapeutics during the 3rd quarter valued at approximately $135,000. Charles Schwab Investment Management Inc. purchased a new position in shares of Artiva Biotherapeutics in the third quarter valued at $623,000. Acuta Capital Partners LLC bought a new stake in Artiva Biotherapeutics in the third quarter worth $680,000. Finally, RTW Investments LP purchased a new stake in Artiva Biotherapeutics during the third quarter valued at $2,300,000.

Artiva Biotherapeutics Stock Down 3.0 %

ARTV traded down $0.38 during trading hours on Thursday, reaching $12.34. 19,782 shares of the company's stock traded hands, compared to its average volume of 125,455. Artiva Biotherapeutics, Inc. has a 52-week low of $9.68 and a 52-week high of $17.31. The company's 50-day moving average price is $12.56.

Artiva Biotherapeutics (NASDAQ:ARTV - Get Free Report) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.92) EPS for the quarter, missing the consensus estimate of ($0.68) by ($0.24). Equities analysts anticipate that Artiva Biotherapeutics, Inc. will post -4.68 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts have recently weighed in on ARTV shares. TD Cowen started coverage on shares of Artiva Biotherapeutics in a report on Tuesday, August 13th. They issued a "buy" rating on the stock. Cantor Fitzgerald started coverage on Artiva Biotherapeutics in a research report on Tuesday, August 13th. They set an "overweight" rating and a $23.00 price objective on the stock. Jefferies Financial Group started coverage on Artiva Biotherapeutics in a report on Tuesday, August 13th. They issued a "buy" rating and a $21.00 target price for the company. Needham & Company LLC restated a "buy" rating and set a $23.00 price target on shares of Artiva Biotherapeutics in a report on Wednesday, November 13th. Finally, Wedbush reaffirmed an "outperform" rating and set a $18.00 price objective on shares of Artiva Biotherapeutics in a research note on Friday, August 30th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus target price of $21.25.

Artiva Biotherapeutics Profile

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.